Ralliant (NYSE:RAL) Sets New 52-Week Low – Here’s Why

Ralliant Corporation (NYSE:RAL) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $37.27 and last traded at $37.7260, with a volume of 2123396 shares changing hands. The stock had previously closed at $56.28.

Ralliant News Summary

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Analyst upgrades: Vertical Research upgraded Ralliant from “hold” to “buy” with a $45 price target, which supports near‑term upside expectations. The Fly: Vertical Research upgrade
• Positive Sentiment: Citigroup maintained a “buy” rating (but trimmed its PT to $51 from $61), which still implies meaningful upside and likely helped calm some selling pressure. Benzinga: Citigroup note
• Positive Sentiment: Quarterly results modestly beat: Q4 EPS of $0.69 (vs. $0.67 est.) and revenue of ~$554.6M (vs. $543M est.), showing underlying operational resilience despite the one‑time items. MarketBeat: Q4 results
• Neutral Sentiment: Company set 2026 revenue target of $2.1B–$2.2B (roughly in line with consensus), which supports the topline outlook but is tempered by other items below. BusinessWire: FY2026 outlook
• Negative Sentiment: Material non‑cash charge: the company recorded a $1.4B goodwill impairment in its Test & Measurement segment (EA Elektro‑Automatik), producing a large reported net loss and triggering the recent sharp selloff. MarketWatch: $1.4B impairment
• Negative Sentiment: Multiple law‑firm investigations and investor notices (Holzer & Holzer, Johnson Fistel, Block & Leviton) are underway into the impairment and disclosures, adding legal/exec‑risk uncertainty. GlobeNewswire: Investor alerts
• Negative Sentiment: Shares recently hit an all‑time low after the impairment and heavy losses were disclosed, which can pressure sentiment until clarity on write‑ups, integration and legal outcomes emerges. InsiderMonkey: All‑time low coverage

Analysts Set New Price Targets

Several analysts have weighed in on RAL shares. Citigroup dropped their price target on Ralliant from $61.00 to $51.00 and set a “buy” rating on the stock in a research note on Friday. Oppenheimer dropped their target price on Ralliant from $60.00 to $50.00 and set an “outperform” rating on the stock in a research report on Friday. Royal Bank Of Canada cut their price target on shares of Ralliant from $52.00 to $41.00 and set a “sector perform” rating on the stock in a report on Friday. Truist Financial decreased their price objective on shares of Ralliant from $62.00 to $49.00 and set a “buy” rating for the company in a research note on Friday. Finally, Barclays raised their target price on shares of Ralliant from $59.00 to $60.00 and gave the stock an “overweight” rating in a report on Wednesday, January 7th. Seven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $51.30.

Ralliant Stock Up 2.9%

The business’s fifty day simple moving average is $51.52 and its two-hundred day simple moving average is $46.72. The company has a market cap of $4.46 billion and a PE ratio of 31.10. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.84 and a quick ratio of 1.03.

Ralliant (NYSE:RAL) last posted its earnings results on Wednesday, February 4th. The company reported $0.69 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.02. The business had revenue of $554.60 million for the quarter, compared to analyst estimates of $543.04 million. The business’s revenue was up 1.2% on a year-over-year basis. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 23rd. Stockholders of record on Monday, March 9th will be given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Monday, March 9th. Ralliant’s payout ratio is presently 15.75%.

Institutional Investors Weigh In On Ralliant

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RAL. Pinnbrook Capital Management LP acquired a new position in shares of Ralliant in the 4th quarter valued at $7,878,000. Covestor Ltd lifted its position in Ralliant by 4,096.7% in the fourth quarter. Covestor Ltd now owns 11,583 shares of the company’s stock valued at $590,000 after buying an additional 11,307 shares during the last quarter. Gabelli Funds LLC boosted its stake in Ralliant by 11.9% during the fourth quarter. Gabelli Funds LLC now owns 29,836 shares of the company’s stock worth $1,519,000 after buying an additional 3,177 shares during the period. Thrivent Financial for Lutherans increased its position in shares of Ralliant by 3.9% during the fourth quarter. Thrivent Financial for Lutherans now owns 218,251 shares of the company’s stock valued at $11,111,000 after acquiring an additional 8,206 shares during the last quarter. Finally, Allworth Financial LP raised its stake in shares of Ralliant by 134.4% in the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after acquiring an additional 293 shares during the period.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.